|Articles|February 1, 1996

Osteoporosis: Epidemiology, Screening, Diagnosis, Treatment, and Prevention
Volume 2
Issue 3 Suppl

Treatment of Osteoporosis

Author(s)Robert Downs, MD, David B. Karpf, MD, John Eisman, PhD, MB

Download PDF: Treatment of Osteoporosis

Articles in this issue

over 30 years ago

Article

Introduction

over 30 years ago

Article

Epidemiology of Low Bone Mass and Fractures

over 30 years ago

Article

Biochemical Markers in the Diagnosis and Treatment of Osteoporosis

over 30 years ago

Article

The Role of Bone Mineral Density in the Diagnosis of Osteoporosis

over 30 years ago

Article

Review Article: Osteoporosis Revisited

over 30 years ago

Article

CME Quiz

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

ByVivian T. E. Tar, PharmD, MBA

July 8th 2026

Readability of Hospital Patient Financial Policy Documents

BySamantha Randall, BA,Sumedha Raghu, MS,Ella Cho,Nina Linh Nguyen, MHA,Erin Trish, PhD,Erin L. Duffy, PhD, MPH

July 7th 2026

Treatment of Osteoporosis

Articles in this issue

Related Content

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Readability of Hospital Patient Financial Policy Documents

Trending on AJMC

Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues

Upcoming 2026 FDA Decisions Could Expand Treatment Options Across Oncology and Hepatitis B

FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

FDA Expands Pembrolizumab-Enfortumab for Muscle-Invasive Bladder Cancer

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Treatment of Osteoporosis

Articles in this issue

Related Content

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Readability of Hospital Patient Financial Policy Documents

Trending on AJMC

Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues

Upcoming 2026 FDA Decisions Could Expand Treatment Options Across Oncology and Hepatitis B

FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

FDA Expands Pembrolizumab-Enfortumab for Muscle-Invasive Bladder Cancer